The high efficacy and low toxicity of proton pump inhibitors (PPIs) has contributed to their frequent prescription worldwide, often without clear indication.

Such widespread over-prescription incurs avoidable financial and clinical costs1. PPI use is associated with a number of adverse consequences including Clostridium difficile infection, community acquired pneumonia, osteoporosis, hypomagnesaemia and kidney injury2-7.

In light of this, PPI prescription should be reserved for patients where there is a clear indication and clinicians should consider stopping PPIs when the indication is unclear. There are data to support stopping PPIs in patients who have been taking them long term.

Printable version of this page

Oral PPIs Department: Pharmacy PDF, 734.1 KB, 9 pages